Improving the outcomes of transplantation with bispecific antibodies
Identifying patients at different risk of relapse in childhood acute lymphoblastic leukemia (ALL)
Overcoming the issues with clinical trial recruitment
New monoclonal antibodies for ALL treatment
Making an IMPACT in ALL therapy: how can cure rates be improved?